42nd Annual J.P. Morgan Healthcare Conference
Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS
These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES
In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.
Revealing the power of genetic science – for everyone

**Mission**
We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

**Vision**
As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.
Myriad Genetics at-a-glance

**A leader in genetic testing**
Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing

**30+ years of scientific and commercial achievements**
1,000+ scientific publications and counting

**45,000+**
active ordering healthcare providers¹

**69**
net promoter score¹

**~2,700**
employees²

**10%+ annual revenue growth for fourth consecutive quarter³**
Commercial execution driving volume growth; price stability

**Market-leading gross margins; healthy balance sheet**

**Innovation in ‘24 and beyond**
Expect to launch multiple differentiated tests in prenatal and oncology through 2026

---

1. As of September 2023
2. As of year-end 2023
3. As of third quarter 2023 and excludes contribution from change of revenue estimates
Pillars of long-term growth and profitability

Science and innovation
Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings

Elevated customer experience and commercial execution
Strong digitally enabled commercial platform

Technology enabled operations
Automated, scalable and cost-effective laboratory operations and technology platform

Scalable commercial, lab operations and administrative support services
Advanced regulatory, reimbursement, and revenue cycle capabilities
3 focus areas: Oncology, Women's Health and Pharmacogenomics

### Oncology
Clarifying cancer treatment with genetic and genomic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.

<table>
<thead>
<tr>
<th>Business</th>
<th>Actionable Market Size*</th>
<th>Channel Customer</th>
</tr>
</thead>
</table>
| $23 Billion | Oncologist | MyRisk®  
Hereditary Cancer Test |
| | Surgeon | Prolaris®  
Prostate Cancer Prognostic Test |
| | Urologist | EndoPredict®  
Breast Cancer Prognostic Test |
| | Genetic Counselor | Precise® Liquid  
Molecular Profile Test |

### Women’s Health
A leader in health and wellness with differentiated genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.

<table>
<thead>
<tr>
<th>Business</th>
<th>Actionable Market Size*</th>
<th>Channel Customer</th>
</tr>
</thead>
</table>
| $5 Billion | OB/GYN | MyChoice® CDx  
Myriad MRD Companion Diagnostic Test |
| | Maternal Fetal Medicine | BRACAnalysis CDx®  
Germline Companion Diagnostic Test |
| | Primary Care | Precise® Tumor  
Molecular Profile Test |
| | Genetic Counselor | Precise® MRD  
Minimal Residual Disease Monitoring |

### Pharmacogenomics
Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

<table>
<thead>
<tr>
<th>Business</th>
<th>Actionable Market Size*</th>
<th>Channel Customer</th>
</tr>
</thead>
</table>
| $5 Billion | Psychiatrist | MyRisk®  
Hereditary Cancer Test |
| | Primary Care | MyChoice® CDx  
Myriad MRD Companion Diagnostic Test |
| | Nurse Practitioner/Physician Assistant | Prolaris®  
Prostate Cancer Prognostic Test |

Source: Data as of 2022 from third-party global consulting firm and internal Company estimates
# Diversified portfolio within large, fragmented, actionable markets

<table>
<thead>
<tr>
<th>Oncology</th>
<th>Women’s Health</th>
<th>PGx</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFFECTED HCT + GERMLINE</td>
<td>TUMOR PROFILING(^3)</td>
<td>MRD</td>
</tr>
<tr>
<td><em>Actionable Market Opp.(^1)</em></td>
<td><strong>$1.2B</strong></td>
<td><strong>$500M</strong></td>
</tr>
<tr>
<td><strong>Market Penetration</strong></td>
<td>~65%</td>
<td>~45%</td>
</tr>
<tr>
<td><strong>Myriad Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>MyRisk</em></td>
<td><em>Precise</em> Tumor</td>
<td><em>Precise</em> MRD</td>
</tr>
<tr>
<td><em>Hereditary Cancer Test</em></td>
<td><em>Molecular Profiling Test</em></td>
<td><em>Molecular Profiling Test</em></td>
</tr>
<tr>
<td><em>BRACAnalysis CDx</em></td>
<td><em>Precise</em> Liquid</td>
<td><em>Bravio® Genomic Warning</em></td>
</tr>
</tbody>
</table>

**$30B** of actionable market opportunity

<40% average market penetration across all categories

<20% of market share concentrated among Top 3 participants

Myriad holds **Top 3 position** in 6 out of 7 active product categories

---

1: Actionable market indicated against cancers of commercial focus
2: In ovarian, breast, prostate, pancreatic cancers only
3: Reflective of IHC partnership

Data as of 2022 from third-party global consulting firm and internal Company estimates.
MyRisk addresses the needs of large and growing markets

**Unaffected Market – Hereditary Screening**

- Actionable market size (US only): ~$3B
- Market penetration*: 15%
- Market growth**: High single digits
- MYGN market share: 30% - 35%

**Affected Market – Germline Screening**

- Actionable market size (US only): ~$1.2B
- Market penetration: 65%
- Market growth**: Mid single digits
- MYGN market share: ~20%

**TOTAL U.S. POPULATION**
- ~332M

**TOTAL U.S. POPULATION WHO WOULD QUALIFY FOR HCT**
- ~50M*

**TOTAL NUMBER OF WOMEN WHO QUALIFY FOR HCT**
- ~25M

**WOMEN WHO QUALIFY FOR HCT AND ARE ACTIVELY INVOLVED IN THEIR HEALTHCARE**
- ~13M

**TOTAL NUMBER OF WOMEN WHO ARE NEWLY ELIGIBLE FOR HCT IN THE PAST YEAR**
- ~800K

**TOTAL NEWLY DX PATIENTS ELIGIBLE TO RECEIVE GERMLINE SCREENING ANNUALLY***
- ~860K

**PATIENTS RECEIVING GERMLINE TESTING ANNUALLY**
- ~550K

* *Data as of 2022 from third-party global consulting firm and internal Company estimates
** Expected
*** In cancers of focus
Significant opportunity to accelerate MyRisk growth across Women’s Health, Imaging, Oncology and Urology

Roadmap of expected highlights

2024
- MyRisk patient portal
- MyRisk Medical Management Tool Enhancements
- RiskScore studies
- Breast Cancer Risk Assessment Program

2025
- Panel Expansion | WES (whole exome sequencing)
- BRAC CDx to NGS

Hereditary cancer test volume

Figures in thousands

Q3’23 LTM Volume Growth (YOY)

+19%


YOY Growth: +4%, +16%, +24%, +20%, +18%
GeneSight is the market-leading PGx test helping address the Nation’s mental health crisis

GeneSight designed to help physicians understand how patients will respond to medications used to treat depression, anxiety, ADHD, and other psychiatric conditions.

2 Million + people have taken the GeneSight test

7 Clinical Studies published in peer reviewed journals, including independent randomized controlled trial in JAMA

Ordered by tens of thousands of clinicians to inform medication selection and dosing

Measures multiple genomic variants for each individual to categorize medications and provide clinical considerations

Market-leading psychiatric PGx test and the only test backed by seven clinical studies published in peer-reviewed journals

Designed to help physicians and patients avoid multiple medication trials by informing which medications may require dose adjustments, be less likely to work, or have increased risk of side effects.
Strong commercial execution driving significant volume growth in the last twelve months

<table>
<thead>
<tr>
<th>Actionable market size (US only)*</th>
<th>Market penetration*</th>
<th>Market growth**</th>
<th>MYGN market share*</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$5B</td>
<td>15%</td>
<td>Mid teens</td>
<td>55-60%</td>
</tr>
</tbody>
</table>

Roadmap of expected highlights

**2024**
- Health Economic Outcome Research (HEOR) study***
- Significant opportunity to improve payor coverage and ASP

**2025**
- Postpartum Clin Dev Protocol & Study

![GeneSight test volume chart](chart)

*Data as of 2022 from third-party global consulting firm and internal Company estimates

**Expected

***This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.
Prolaris designed to help determine optimal treatment planning for patients with localized prostate cancer

Prolaris utilizes two validated thresholds to identify men that are:
- Safe for active surveillance (low-risk patients)
- Candidates for a singular type of therapy (medium-risk patients)
- Candidates for multiple types of therapy at once (high-risk patients)

Lower Prolaris score

- Active surveillance (low-risk patients)
- Single-modal treatment (medium-risk patients)
- Multi-modal treatment (high-risk patients)

Higher Prolaris score


RESEARCH VALIDATION

Prolaris identified >86% of low-risk patients as candidates for active surveillance*
Strong runway for Prolaris with an opportunity to capture more market share with compelling updates

---

**Roadmap of expected highlights**

2024
- Expanded coverage from UnitedHealthcare
- ARR (Absolute Risk Reduction) report
- Publish 3-yr Metastasis study

2025
- Prolaris Post-RP launch

---

**Actionable market size (US only)**
- ~$600M

**Market penetration**
- 35%

**Market growth**
- Low teens

**MYGN market share**
- ~40%

---

**Prolaris test volume**

Figures in thousands

- **Q3'23 LTM Volume Growth (Y.O.Y.) +15%**

*Data as of 2022 from third-party global consulting firm and internal Company estimates*

**Expected**
Comprehensive prenatal care with differentiated products and reliable technology

**Prequel®**

Prenatal Screen

Shown to deliver accurate answers to patients regardless of age, ancestry, or body mass index—the Prequel Prenatal Screen with AMPLIFY™ helps determine a pregnancy’s risk for a variety of chromosomal conditions.

- AMPLIFY fetal fraction amplification delivers first-time accurate results to >99.9% of patients at 10 weeks.*
- Industry-low screening failure rate** reduces the chance of repeat screens or unnecessary, invasive diagnostics such as amniocentesis.

**Foresight®**

Carrier Screen

Foresight identifies couples at risk of passing down serious, inherited conditions to their children to guide informed planning, preparation and care.

- Highest published at-risk couple detection rate for serious conditions (1 in 22 couples)***
- >99% detection rate for the vast majority of genes in couples across all ancestries

---


A market that continues to grow with potential tailwinds from guideline expansion

**Roadmap of expected highlights**
- 2024 Foresight on NovaSeq
- FirstGene Launch
- Various Prequel studies
- Foresight Universal Plus

<table>
<thead>
<tr>
<th>Actionable market size (US only)*</th>
<th>Market penetration*</th>
<th>Market growth**</th>
<th>MYGN market share*</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$1.3B</td>
<td>45-55%</td>
<td>Low single digits</td>
<td></td>
</tr>
<tr>
<td>~$950M</td>
<td>40-50%</td>
<td>Low single digits</td>
<td>Mid teens</td>
</tr>
</tbody>
</table>

**Prenatal test volume excl. SneakPeek**

三国’23 LTM Volume Growth (YOY)

*Data as of 2022 from third-party global consulting firm and internal Company estimates
**Expected
### Operational highlights fueling our growth

#### Team Engagement
- **86%**
  - Of our team rate Myriad as a “Great Place To Work”

#### Market Perception and Customer Service Levels
- **69%**
  - Net Promoter Score among current Myriad providers ordering across our testing portfolio

- **+1300 bps**
  - Favorable consideration among providers aware of our efforts to share data with ClinVar*

#### Efficiency & Speed
- **5.7 days**
  - Rapid turn-around times critical for patients making time-sensitive care decisions

- **8%**
  - YOY reduction in COGS per test scaling with growth, quality and regulatory requirements**

- **+20%**
  - YOY sales productivity increase with structural optimization, automation and accelerating marketing demand

#### Revenue Cycle
- **+$58M**
  - Increase in collections from 2021 to 2023 with fully automated revenue cycle platform

- **54 Days**
  - Industry leading Days Sales Outstanding (DSO) improved 7 days from Q3 ‘22

- **+$40M**
  - Estimated revenue opportunity through 2026 from improving revenue cycle operations

---

All data as of September 30, 2023 except as otherwise noted

* SOURCE: 2022 survey conducted by Edelman HCP ETM Pulse 2022. Next time you need to recommend testing to a patient, how likely are you to consider recommending testing from the following company(s) assuming they provide the type of testing your patient needs, and you have the opportunity to choose? December 2022 Base: HCPs who were not aware of the Clinvar Announcement (n=65) / HCPs who were aware of the Clinvar Announcement (n=114)

** Excluding contribution from SneakPeak Early Gender DNA test
## Enterprise infrastructure and capability investments

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
</tr>
<tr>
<td><strong>NovaSeq Transitions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prenatal products shift to advanced sequencing</td>
<td>![1H]</td>
<td>![1H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MyChoice products shift to advanced sequencing</td>
<td>![2H]</td>
<td>![2H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Whole Exome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expanding exome capability to undergird MyRisk, Foresight, Precise, and other products</td>
<td>![1H]</td>
<td>![1H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>New Facility Construction</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South San Francisco innovation campus construction</td>
<td>![1H]</td>
<td>![1H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salt Lake City production lab campus construction</td>
<td>![1H]</td>
<td>![1H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Shift Operations to New Facilities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Innovation operations to new South San Francisco facility</td>
<td>![2H]</td>
<td>![2H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Prenatal production to Salt Lake City</td>
<td>![2H]</td>
<td>![2H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Salt Lake City Research Park products to new campus</td>
<td>![2H]</td>
<td>![2H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Advanced Automation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Design and build first phases of automation</td>
<td>![1H]</td>
<td>![1H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early phase Prenatal lab automation</td>
<td>![2H]</td>
<td>![2H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fully automate Prenatal labs</td>
<td>![2H]</td>
<td>![2H]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EMR integrations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accelerating pace of EMR integrations through EMR providers EPIC, Athena and Flatiron (estimate ~1,200 new integrations in 2023, ~1,850 in 2024)</td>
<td>![1H]</td>
<td>![1H]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*$ >85% of investment is estimated to be capitalizable expense*

**$80M* investment in modern labs**

**$12M annual savings starting in 2025**
Product roadmap summary

<table>
<thead>
<tr>
<th>Product</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>MyRisk® Hereditary Cancer Test</td>
<td>Tyrer-Cuzick v8 3Q</td>
<td>MyRisk patient portal 4Q</td>
<td>MyRisk Panel expansion 3Q</td>
</tr>
<tr>
<td>Prolaris® Prostate Cancer Prognostic Test</td>
<td>ARR 3Q</td>
<td>Pathology AI (discovery) 2H</td>
<td>Prolaris Post RP 2H</td>
</tr>
<tr>
<td>Foresight® Carcin Screen</td>
<td>Foresight Universal Plus 1Q</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FirstGene® Multiple Pediatric Screen</td>
<td>Validation 1Q</td>
<td>Study 4Q</td>
<td>Full Launch 4Q</td>
</tr>
<tr>
<td>MyChoice® CDx Myriad MRI Companion Diagnostic Test</td>
<td></td>
<td>Indication Expansion (e.g. Breast and Prostate) 2H</td>
<td></td>
</tr>
<tr>
<td>Precise® Liquid Molecular Profile Test</td>
<td></td>
<td></td>
<td>Launch 3Q</td>
</tr>
<tr>
<td>Precise® MRD Minimal Residual Disease Monitoring</td>
<td>RUO (Research Only)</td>
<td>Pharma Availability</td>
<td>Comm’l Launch 2H</td>
</tr>
</tbody>
</table>
## Active pipeline to better serve patients and providers

### Women's Health

**FirstGene™**
- *Multiple prenatal screen*

**Foresight™ Universal Plus**
- *Expanded carrier screen*

**Key advantages**
- Faster turnaround time
- 3x lower cost of goods
- Established reimbursement

### Oncology

**Precise™ Tumor**
- *Robust tumor profiling & therapy selection*

**Key Advantages**
- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

**Precise™ Liquid**
- *Robust tumor profiling & therapy selection*

**Key Advantages**
- Panel size ~2x size (500 genes) of lead competitor; uses DNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

**Precise™ MRD**
- *Minimal residual disease monitoring*

**What is It?**
- Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions

**Key Advantages**
- Targets 10x variants
- Known path to reimbursement

**Women's Health**

**Foresight™ Universal Plus**
- Pioneering expanded carrier screen that uses NGS to find pathogenic variants underlying recessive disease. 274 gene expansion in ACOG guidelines (anticipated.)

**Key Advantages**
- Merged couple reporting
- Fully automated lab workflow drives low COGS

**Precise™ Tumor**
- Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering or as reflex if solid tumor is insufficient

**Key Advantages**
- Program size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path
FirstGene: Transformative prenatal screen running multiple tests at once

Current PROBLEMS with prenatal genetic screening

- Providers don’t have enough time to talk about genetics
- Only 50% utilization of carrier screening
- Only 30% of fathers get screened when mother is a carrier
- Low gross margins on NIPS and ECS

New SOLUTION

- Easier for providers to administer integrated offering
- No need to screen the father
- Estimated 30-40% higher gross margins compared to Foresight or Prequel alone
Oncology: Expanding breadth of portfolio addressing real-world community needs

- **MyRisk** Hereditary Cancer Test
- **RiskScore**
- **Prolaris** Prostate Cancer Prognostic Test
- **EndoPredict** Breast Cancer Prognostic Test
- **MyChoice CDx** Myriad IKG Companion Diagnostic Test
- **Precise Tumor** Molecular Profile Test
- **BRACAnalysis CDx** Germline Companion Diagnostic Test

**Planned Product Expansion**

- **High Risk Screening**
- **Surgical Decisions**
- **Prognostic Testing**
- **Treatment Selection & Clinical Trials**
- **Measurable Residual Disease**
- **Monitoring Recurrence**

- **2024E Launch expected**
  - **Precise Liquid** Molecular Profile Test
  - Therapeutic Selection

- **2025E Launch expected**
  - **Precise MRD** Minimal Residual Disease Monitoring

©2024 Myriad Genetics, Inc.
High-definition MRD: Differentiation built upon existing competencies

Comparative Analysis

Comparable Myriad test
MyChoice® CDx
Myriad HRD Companion Diagnostic Test

FirstGene®
Multiple Prenatal Screen

Existing and proprietary* chemistry and technology

More Targeted tumor sites increases sensitivity

Competitor
16 sites

Myriad
1000 sites

Monitoring Test Economics - Gross Margin (Est.) per Patient

Higher sensitivity: detection at 10x lower tumor levels

100x more of the genome explored

Over 60x more targeted sites

Earlier detection of recurrence

*patients pending
Precise MRD: Partnerships with world-leading collaborators

“...We anticipate the MRD test from Myriad will be more sensitive and specific than many other ctDNA offerings for monitoring the response and, therefore, may more accurately identify the patients who will or will not benefit from certain therapies. Importantly, some of these patients may go undetected on a less-sensitive MRD test.”

Dr. Pedram Razavi
Director of Liquid Biopsy & Genomics
Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering
Breast cancer: Two-phase study of 100 patients with metastatic breast cancer in neoadjuvant and adjuvant setting

MD Anderson Cancer Center
Renal cancer: Testing 120 patients with recurrent RCC to assess clinical validity on Radiation + MRD
Financial Highlights
2023 revenue, adjusted gross margin, adjusted opex and adjusted EPS by quarter

All figures in millions, except per share amounts

<table>
<thead>
<tr>
<th>Total revenue</th>
<th>Adjusted Gross Margin*</th>
<th>Adjusted Operating Expense*</th>
<th>Adjusted EPS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>$155</td>
<td>$181.2</td>
<td>$145</td>
<td>$(0.24)</td>
</tr>
<tr>
<td>Q1 '23</td>
<td>Q1 '23</td>
<td>Q1 '23</td>
<td>Q1 '23</td>
</tr>
<tr>
<td>$195</td>
<td>$183.5</td>
<td>$144.5</td>
<td>(0.08)</td>
</tr>
<tr>
<td>Q2 '23</td>
<td>Q2 '23</td>
<td>Q3 '23</td>
<td>Q2 '23</td>
</tr>
<tr>
<td>191.9</td>
<td>67.7%</td>
<td>133.4</td>
<td>(0.03)</td>
</tr>
<tr>
<td>Q3 '23</td>
<td>Q3 '23</td>
<td>Q4 '23</td>
<td>Q3 '23</td>
</tr>
<tr>
<td></td>
<td>69.0%</td>
<td>137.3</td>
<td>$0.00</td>
</tr>
<tr>
<td>Q4 '23E</td>
<td>Q4 '23E</td>
<td></td>
<td>(0.03)</td>
</tr>
</tbody>
</table>

2023 guidance: $747 - $753  69% - 70%  $548 - $553  $(0.33) - $(0.28)

*Fiscal year 2023 non-GAAP guidance begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $40 million, non-cash amortization associated with acquisitions of approximately $48 million and special items such as costs related to transformation initiatives of approximately $24 million, legal settlement costs of approximately $114 million, and tax adjustments of approximately $8 million.

Q4 '23E figures reflect the amount to achieve the mid-point of the 2023 guidance range.
## Reaffirm 2023 revenue and non-GAAP financial guidance and long-term financial targets

All figures in millions, except per share amounts

<table>
<thead>
<tr>
<th></th>
<th>2023 financial guidance</th>
<th>2023 comments</th>
<th>2024 - 2026 commentary</th>
<th>additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenue</td>
<td>$747 - $753</td>
<td>2023 annual growth between 10% - 11% over 2022.</td>
<td>10%+ CAGR</td>
<td>Target total revenue of over $1 billion in 2026. This revenue target includes modest contribution from planned new products and no contribution from future M&amp;A.</td>
</tr>
<tr>
<td>Gross margin %</td>
<td>69% - 70%</td>
<td>GM expected to fluctuate in any quarter given seasonality.</td>
<td>70%+</td>
<td>GM expected to fluctuate in any quarter given product mix, pricing trends and seasonality.</td>
</tr>
<tr>
<td>Adjusted operating expenses*</td>
<td>$548 - $553</td>
<td></td>
<td>5-6% CAGR</td>
<td>Balance ongoing investment in R&amp;D with ongoing cost controls in SG&amp;A.</td>
</tr>
<tr>
<td>Adjusted EPS*</td>
<td>$(0.33) - $(0.28)</td>
<td>Adjusted EPS is expected to reach positive adjusted profitability and adjusted operating cash flow in Q4 ‘23.</td>
<td>Positive adjusted operating income and adjusted cash flow</td>
<td>Target adjusted operating income of approximately $100 million in 2026**, or 10% of total revenue in 2026. Adjusted operating cash flow is expected to be in-line with adjusted operating income trend.</td>
</tr>
</tbody>
</table>

Assumes currency rates as of November 6, 2023

* Fiscal year 2023 non-GAAP guidance begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $40 million, non-cash amortization associated with acquisitions of approximately $48 million and special items such as costs related to transformation initiatives of approximately $24 million, legal settlement costs of approximately $114 million, and tax adjustments of approximately $8 million

** 2026 adjusted operating income target begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $46.0 million, non-cash amortization associated with acquisitions of approximately $43.0 million and special items such as costs related to transformation initiatives of approximately $4.0 million
Increased financial flexibility; On-track to achieve positive adjusted operating cash flow in Q4 ‘23

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cash and cash equivalents at end of third quarter of 2023*</td>
<td>$86.3</td>
</tr>
<tr>
<td>Amount available to draw under the asset-based credit facility**</td>
<td>28.2</td>
</tr>
<tr>
<td>Net proceeds from follow-on equity offering</td>
<td>117.6</td>
</tr>
<tr>
<td>Cash payment of securities class action settlement and first Ravgen installment in Q4 2023</td>
<td>(62.5)</td>
</tr>
<tr>
<td>Estimated capital expenditures, capitalization of internal-use software costs and cash flow from operations in Q4 ’23</td>
<td>(7.0)</td>
</tr>
<tr>
<td>Estimated total available cash and cash equivalents and availability under credit facility at year end 2023</td>
<td>$162.6</td>
</tr>
</tbody>
</table>

* Cash and cash equivalents at the end of the Q3 ‘23 reflects the initial cash payment of $20 million for the securities class action settlement

** The amount available to draw under the ABL facility is based on the ABL facility of $115 million. In October 2023, Myriad increased the size of the ABL facility by $25 million to $115 million.

Raised net $118 million in upsized and oversubscribed equity offering

Increased size of asset-based credit facility to $115 million from $90 million.
## Well positioned to take advantage of future market opportunities

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue growth expected to accelerate 10%+ in ‘24–’26</td>
<td>Provided 2024 full-year revenue guidance of $815 - $835 million reflecting annual growth of 9-11% over midpoint of 2023 revenue guidance range</td>
</tr>
<tr>
<td>Right to win with core products driving market share gains</td>
<td>Enhanced commercial execution generating double-digit volume growth as adoption rates and competitive position improves</td>
</tr>
<tr>
<td>Pipeline addresses large growth markets</td>
<td>Robust and differentiated product pipeline opens access to incremental multi-billion-dollar markets</td>
</tr>
<tr>
<td>Operating leverage, profitability, and positive cash flow</td>
<td>Strength of business model, technology platform and enhanced laboratory capabilities to drive operating leverage, profitability and cash flow in 2024–2026</td>
</tr>
<tr>
<td>Capital deployment</td>
<td>Disciplined capital deployment; continue to invest in high ROI opportunities within core channels</td>
</tr>
</tbody>
</table>
Appendix
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022
(unaudited data in millions, except per share amounts)

### Adjusted Gross Margin

<table>
<thead>
<tr>
<th></th>
<th>Three months ended</th>
<th></th>
<th>Nine months ended</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 30,</td>
<td>2023</td>
<td>$134.3</td>
<td>2022</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$382.0</td>
<td>2023</td>
</tr>
<tr>
<td>GAAP Gross Profit(1)</td>
<td></td>
<td>$134.3</td>
<td>$382.0</td>
<td></td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>0.4</td>
<td>-</td>
<td>1.0</td>
<td>-</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>0.4</td>
<td>0.4</td>
<td>1.1</td>
<td>1.0</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>-</td>
<td>-</td>
<td>0.2</td>
<td>-</td>
</tr>
<tr>
<td><strong>Adjusted Gross Profit</strong></td>
<td><strong>$135.1</strong></td>
<td><strong>$106.4</strong></td>
<td><strong>$384.3</strong></td>
<td><strong>$353.5</strong></td>
</tr>
<tr>
<td>Adjusted Gross Margin</td>
<td>70.4%</td>
<td>68.0%</td>
<td>69.0%</td>
<td>70.6%</td>
</tr>
</tbody>
</table>

(1) Consists of total revenues less cost of testing from the Condensed Consolidated Statements of Operations.

### Adjusted Operating Expenses

<table>
<thead>
<tr>
<th></th>
<th>Three months ended</th>
<th></th>
<th>Nine months ended</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 30,</td>
<td>2023</td>
<td>$194.4</td>
<td>2022</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$608.0</td>
<td>2023</td>
</tr>
<tr>
<td>GAAP Operating Expenses(1)</td>
<td>$194.4</td>
<td>$151.0</td>
<td>$608.0</td>
<td>$440.9</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>(10.3)</td>
<td>(10.1)</td>
<td>(31.0)</td>
<td>(30.4)</td>
</tr>
<tr>
<td>Goodwill and long-lived asset impairment charges</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(10.7)</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>(11.3)</td>
<td>(9.0)</td>
<td>(29.2)</td>
<td>(28.7)</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>(2.8)</td>
<td>(4.7)</td>
<td>(20.6)</td>
<td>(12.4)</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>(35.1)</td>
<td>-</td>
<td>(113.3)</td>
<td>12.9</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>2.4</td>
<td>(0.2)</td>
<td>1.6</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Adjusted Operating Expenses</strong></td>
<td><strong>$137.3</strong></td>
<td><strong>$127.0</strong></td>
<td><strong>$415.5</strong></td>
<td><strong>$372.3</strong></td>
</tr>
</tbody>
</table>

(1) Consists of research and development expense, selling, general, and administrative expense, and goodwill and long-lived asset impairment charges from the Condensed Consolidated Statements of Operations.
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended</th>
<th>Nine months ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 30</td>
<td>September 30</td>
</tr>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td><strong>Adjusted Operating Income (Loss)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Operating Loss</td>
<td>(60.1)</td>
<td>(45.0)</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>10.7</td>
<td>10.1</td>
</tr>
<tr>
<td>Goodwill and long-lived asset impairment charges</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>11.7</td>
<td>9.4</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>2.8</td>
<td>4.7</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>35.1</td>
<td>–</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>(2.4)</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Adjusted Operating Loss</strong></td>
<td>(2.2)</td>
<td>(20.6)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Three months ended</th>
<th>Nine months ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 30</td>
<td>September 30</td>
</tr>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td><strong>Adjusted Net Income (Loss)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Net Loss</td>
<td>(61.3)</td>
<td>(35.1)</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>10.7</td>
<td>10.1</td>
</tr>
<tr>
<td>Goodwill and long-lived asset impairment charges</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>11.7</td>
<td>9.4</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>2.8</td>
<td>4.7</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>35.1</td>
<td>–</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>(1.7)</td>
<td>0.2</td>
</tr>
<tr>
<td>Tax adjustments</td>
<td>0.4</td>
<td>(4.5)</td>
</tr>
<tr>
<td><strong>Adjusted Net Loss</strong></td>
<td>(2.3)</td>
<td>(15.2)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weighted average shares outstanding:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic</td>
<td>61.9</td>
<td>61.6</td>
</tr>
<tr>
<td>Diluted</td>
<td>81.0</td>
<td>81.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjusted Earnings Per Share</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic</td>
<td>$(0.03)</td>
<td>$(0.19)</td>
</tr>
<tr>
<td>Diluted</td>
<td>$(0.03)</td>
<td>$(0.19)</td>
</tr>
</tbody>
</table>

(1) To determine Adjusted Earnings Per Share, or adjusted EPS.
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

*(unaudited data in millions, except per share amounts)*

<table>
<thead>
<tr>
<th></th>
<th>Three months ended September 30,</th>
<th>Nine months ended September 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td>Cash flow from operations</td>
<td>$ (20.6)</td>
<td>$ (1.8)</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>2.8</td>
<td>4.7</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>21.1</td>
<td>-</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Adjusted operating cash flow</td>
<td>$ (2.7)</td>
<td>$ 2.9</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>(10.9)</td>
<td>(17.7)</td>
</tr>
<tr>
<td>Capitalization of internal-use software costs</td>
<td>(2.1)</td>
<td>-</td>
</tr>
<tr>
<td>Adjusted free cash flow</td>
<td>$ (15.7)</td>
<td>$ (14.8)</td>
</tr>
</tbody>
</table>
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
- Goodwill and long-lived asset impairment charges – impairment charges on long-lived assets and goodwill.
- Equity compensation – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- Transformation initiatives – transitory costs such as consulting and professional fees related to transformation initiatives, additional rent as a result of the build-out of the company’s new laboratories in Salt Lake City, Utah and in South San Francisco, California, while maintaining its current laboratories in those locations, re-location costs of equipment to new laboratories, severance costs, and accelerated depreciation in connection with the company’s decision to cease the use of its former corporate headquarters in Salt Lake City, Utah. With respect to the adjusted free cash flow reconciliation, the cash flow effect of transformation initiatives excludes non-cash items such as accelerated depreciation.
- Legal charges, net of insurance reimbursement – one-time legal expenses, net of insurance reimbursement. For the three months ended September 30, 2023, legal charges, net of insurance reimbursement primarily relates to a $34.0 million settlement of the Ravgen litigation, of which $21.25 million of payment is contingent upon certain future events. For the nine months ended September 30, 2023, legal charges, net of insurance reimbursement primarily includes the amounts related to the settlement of the Ravgen litigation and a $77.5 million settlement of the securities class action lawsuit. For the nine months ended September 30, 2022, legal charges, net of insurance reimbursement includes the gain from reimbursement of prior legal expenses and settlements. With respect to the adjusted free cash flow reconciliation, the cash flow effect includes cash paid for settlements in the related period.
- Other adjustments – other one-time non-recurring expenses including consulting and professional fees related to prior year acquisitions, changes in the fair value of contingent consideration related to acquisitions from prior years and reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity.
- Tax adjustments – tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. A valuation allowance of $37.2 million was not recognized for non-GAAP purposes given the company’s historical and forecasted positive earnings performance.